Highlight
– The replication‑competent rVSVΔG‑LASV‑GPC vaccine induced robust binding and neutralizing antibody and cellular responses in healthy adults across a wide dose range.
– No vaccine‑related serious adverse events or sensorineural hearing loss were observed; reactogenicity was dose‑dependent and transient.
